drugset / Trial / NCT00511667

A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)

NCT00511667

Phase 1 Completed 70 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A multiple dose study to assess the safety and pharmacokinetics of an investigational drug in patients with type 2 diabetes. The primary hypotheses of the study are that multiple daily MK-0941 in subjects with T2DM with or without adequate control on metformin will be sufficiently safe and well tolerated to permit continued clinical investigation.

Timeline

Start
2007-05
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-0941 Small molecule 10 mg
Subject MK-0941 Small molecule 20 mg
Subject MK-0941 Small molecule 30 mg
Subject MK-0941 Small molecule 40 mg
Subject MK-0941 Small molecule 60 mg